U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H26N4O2.2C2H6O4S
Molecular Weight 606.709
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HEXAMIDINE DIISETHIONATE

SMILES

OCCS(O)(=O)=O.OCCS(O)(=O)=O.NC(=N)C1=CC=C(OCCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1

InChI

InChIKey=NBVZMBLJRHUOJR-UHFFFAOYSA-N
InChI=1S/C20H26N4O2.2C2H6O4S/c21-19(22)15-5-9-17(10-6-15)25-13-3-1-2-4-14-26-18-11-7-16(8-12-18)20(23)24;2*3-1-2-7(4,5)6/h5-12H,1-4,13-14H2,(H3,21,22)(H3,23,24);2*3H,1-2H2,(H,4,5,6)

HIDE SMILES / InChI
Molecular Formula C20H26N4O2
Molecular Weight 354.446
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C2H6O4S
Molecular Weight 126.132
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Hexamidine diisethionate has been used in the personal care industry and in a number of over-the-counter (OTC) drug products as an antimicrobial agent. It was shown, that hexamidine diisethionate plays a beneficial role in skin homoeostasis.

Approval Year

2017
411
PubMed

PubMed

TitleDatePubMed
Antiseptic properties of two calix[4]arenes derivatives on the human coronavirus 229E.
2010-12
[Effect of psychotropic drugs on activity of anticonvulsants in maximal electroshock test].
2010-08
Action potential-enhanced ATP release from taste cells through hemichannels.
2010-08
Cationic compounds with activity against multidrug-resistant bacteria: interest of a new compound compared with two older antiseptics, hexamidine and chlorhexidine.
2010-05
[Infectious keratitis and cosmetic lenses: a five-case retrospective study].
2010-04
[Acanthamoeba keratitis. Report of 3 cases diagnosed in central Tunisia].
2010-02
Treatment with voriconazole in 3 eyes with resistant Acanthamoeba keratitis.
2010-01
Painless Acanthamoeba keratitis in a soft contact lens wearer--case report.
2009-09
p-Guanidinoethyl calixarene and parent phenol derivatives exhibiting antibacterial activities. Synthesis and biological evaluation.
2009-08-01
A new Sephadex-based method for removing microbicidal and cytotoxic residues when testing antiseptics against viruses: Experiments with a human coronavirus as a model.
2009-08
Understanding metabolic pathways for skin anti-aging.
2009-07
Prevalence and risk factors for allergic contact dermatitis to topical treatment in atopic dermatitis: a study in 641 children.
2009-05
Rapidly progressive cataract and iris atrophy during treatment of Acanthamoeba keratitis.
2008-05
Bilateral acanthamoeba keratitis.
2008-02
Visual outcome and rehabilitation in a case of bilateral acanthamoeba sclerokeratitis.
2007-10
In vitro activity of para-guanidinoethylcalix[4]arene against susceptible and antibiotic-resistant Gram-negative and Gram-positive bacteria.
2007-09
Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor.
2007-09
[Acanthamoeba keratitis: about the first two Tunisian cases].
2007-02
Final report on the safety assessment of Hexamidine and Hexamidine Diisethionate.
2007
[Clinical tolerance of cutaneous antiseptics in 3,403 patients in France].
2006-10
Systemic allergy to topical hexamidine.
2006-08-07
[Towards new antibacterial drugs. Interest of para-guanidinoethylcalix[4]arene].
2006-06-19
A keratitis rat model for evaluation of anti-Acanthamoeba polyphaga agents.
2006-06
Acanthamoeba keratitis in a 5-year-old boy without a history of contact lens usage.
2006-04
[Contact allergy to antiseptics: 75 cases analyzed by the dermato-allergovigilance network (Revidal)].
2005-12
Acanthamoeba keratitis during orthokeratology.
2005-10
Crystal structures of QacR-diamidine complexes reveal additional multidrug-binding modes and a novel mechanism of drug charge neutralization.
2004-04-02
Opportunistic amoebae: challenges in prophylaxis and treatment.
2004-02
Persistently culture positive acanthamoeba keratitis: in vivo resistance and in vitro sensitivity.
2003-08
Bilateral Acanthamoeba keratitis with late recurrence of the infection in a corneal graft: a case report.
2003-04
[Treatment of Acanthamoeba keratitis: possibilities, problems, and new approaches].
2003
Structure-based approach for the discovery of bis-benzamidines as novel inhibitors of matriptase.
2001-04-26
1,5-Bis(4-amidinophenoxy)pentane (pentamidine) is a potent inhibitor of [3H]idazoxan binding to imidazoline I2 binding sites.
1998-07-17
Structure-activity relationships of analogs of pentamidine against Plasmodium falciparum and Leishmania mexicana amazonensis.
1990-07
Analogues of 1,5-bis(4-amidinophenoxy)pentane (pentamidine) in the treatment of experimental Pneumocystis carinii pneumonia.
1990-04
Patents

Patents

07994225
2
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:53:51 GMT 2025
Edited
by admin
on Mon Mar 31 18:53:51 GMT 2025
Record UNII
023XA5Z50L
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HEXAMIDINE DIISETHIONATE
INCI  
INCI  
Official Name English
HEXAMIDINE ISETIONATE
MART.   WHO-DD  
Preferred Name English
Hexamidine isetionate [WHO-DD]
Common Name English
4,4'-(HEXAMETHYLENEDIOXY)DIBENZAMIDINE ISETHIONATE
Systematic Name English
HEXAMIDINE DIISETIONATE [EP MONOGRAPH]
Common Name English
HEXAMIDINE DIISETIONATE
EP  
Common Name English
HEXAMIDINE ISETIONATE [MART.]
Common Name English
HEXAMIDINE ISETHIONATE
MI  
Common Name English
HEXOMEDIN
Brand Name English
HEXAMIDINE ISETHIONATE [MI]
Common Name English
RF-2535
Code English
HEXAMIDINE DIISETIONATE [EP IMPURITY]
Common Name English
NSC-115848
Code English
4,4'-(HEXAMETHYLENEDIOXY)DIBENZAMIDINE BIS(2-HYDROXYETHANESULPHONATE)
Systematic Name English
Code System Code Type Description
MERCK INDEX
m6000
Created by admin on Mon Mar 31 18:53:51 GMT 2025 , Edited by admin on Mon Mar 31 18:53:51 GMT 2025
PRIMARY Merck Index
MESH
C018961
Created by admin on Mon Mar 31 18:53:51 GMT 2025 , Edited by admin on Mon Mar 31 18:53:51 GMT 2025
PRIMARY
EPA CompTox
DTXSID60984372
Created by admin on Mon Mar 31 18:53:51 GMT 2025 , Edited by admin on Mon Mar 31 18:53:51 GMT 2025
PRIMARY
DAILYMED
023XA5Z50L
Created by admin on Mon Mar 31 18:53:51 GMT 2025 , Edited by admin on Mon Mar 31 18:53:51 GMT 2025
PRIMARY
ECHA (EC/EINECS)
211-533-5
Created by admin on Mon Mar 31 18:53:51 GMT 2025 , Edited by admin on Mon Mar 31 18:53:51 GMT 2025
PRIMARY
CAS
659-40-5
Created by admin on Mon Mar 31 18:53:51 GMT 2025 , Edited by admin on Mon Mar 31 18:53:51 GMT 2025
PRIMARY
NSC
115848
Created by admin on Mon Mar 31 18:53:51 GMT 2025 , Edited by admin on Mon Mar 31 18:53:51 GMT 2025
PRIMARY
FDA UNII
023XA5Z50L
Created by admin on Mon Mar 31 18:53:51 GMT 2025 , Edited by admin on Mon Mar 31 18:53:51 GMT 2025
PRIMARY
EVMPD
SUB12021MIG
Created by admin on Mon Mar 31 18:53:51 GMT 2025 , Edited by admin on Mon Mar 31 18:53:51 GMT 2025
PRIMARY
PUBCHEM
3080571
Created by admin on Mon Mar 31 18:53:51 GMT 2025 , Edited by admin on Mon Mar 31 18:53:51 GMT 2025
PRIMARY
SMS_ID
100000080187
Created by admin on Mon Mar 31 18:53:51 GMT 2025 , Edited by admin on Mon Mar 31 18:53:51 GMT 2025
PRIMARY
RXCUI
1939371
Created by admin on Mon Mar 31 18:53:51 GMT 2025 , Edited by admin on Mon Mar 31 18:53:51 GMT 2025
PRIMARY
Related Record Type Details
Structure of Isethionic acid
PARENT -> SALT/SOLVATE
Structure of HEXAMIDINE
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of HEXAMIDINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966